IBO
Impact Biomedical Inc
AMEX · Pharmaceuticals
$0.47
-0.01 (-2.98%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.01M | 2.09M | 2.10M |
| Net Income | 252.5K | 255.6K | 224.6K |
| EPS | — | — | — |
| Profit Margin | 12.5% | 12.2% | 10.7% |
| Rev Growth | +12.9% | +6.5% | +8.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.92M | 2.21M | 2.19M |
| Total Equity | 3.68M | 3.82M | 3.64M |
| D/E Ratio | 0.52 | 0.58 | 0.60 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 413.4K | 402.4K | 414.7K |
| Free Cash Flow | 302.8K | 206.2K | 229.1K |